Literature DB >> 17307755

NKT cells: manipulable managers of joint inflammation.

K Coppieters1, P Dewint, K Van Beneden, P Jacques, S Seeuws, G Verbruggen, D Deforce, D Elewaut.   

Abstract

The importance of T cell participation in the aetiology and pathogenesis of rheumatoid arthritis (RA) is now widely appreciated. The disease is mediated by activated pro-inflammatory, self-reactive T helper cells, instigating the chronic autoimmune response characteristic of rheumatoid inflammation. Natural killer T (NKT) cells are a distinctive population of T cells thought to protect self-tissues from damaging inflammatory immune responses, and are often recognized as a regulatory T cell subtype, regulating the magnitude or class of the immune response. Recently, a number of studies have provided insight concerning the role of NKT cells in different models of autoimmune joint inflammation, suggesting the involvement of this specialized T cell subset in controlling initiation and perpetuation of arthritic disease. The aim of this review is to provide rheumatologists with an introduction of the principal features of NKT cells, to give an overview of the data obtained in animal models of arthritis and to discuss the hypothesized mechanisms. Finally, we will speculate on future prospects with regard to NKT cell-targeted treatment of arthritic disease by use of glycolipids.

Entities:  

Mesh:

Year:  2007        PMID: 17307755     DOI: 10.1093/rheumatology/kel437

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

Review 1.  What rheumatologists need to know about innate lymphocytes.

Authors:  Mark A Exley; George C Tsokos; Kingston H G Mills; Dirk Elewaut; Ben Mulhearn
Journal:  Nat Rev Rheumatol       Date:  2016-09-02       Impact factor: 20.543

Review 2.  Invariant natural killer T cells: bridging innate and adaptive immunity.

Authors:  Luc Van Kaer; Vrajesh V Parekh; Lan Wu
Journal:  Cell Tissue Res       Date:  2010-08-24       Impact factor: 5.249

Review 3.  The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

Authors:  Jeff J Subleski; Qun Jiang; Jonathan M Weiss; Robert H Wiltrout
Journal:  Immunotherapy       Date:  2011-10       Impact factor: 4.196

Review 4.  Cell-cell interactions in rheumatoid arthritis synovium.

Authors:  David A Fox; Alison Gizinski; Rachel Morgan; Steven K Lundy
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

5.  Modulation of IL-17 and Foxp3 expression in the prevention of autoimmune arthritis in mice.

Authors:  Joana Duarte; Ana Agua-Doce; Vanessa G Oliveira; João Eurico Fonseca; Luis Graca
Journal:  PLoS One       Date:  2010-05-10       Impact factor: 3.240

Review 6.  Natural killer T cells in health and disease.

Authors:  Lan Wu; Luc Van Kaer
Journal:  Front Biosci (Schol Ed)       Date:  2011-01-01

7.  NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab.

Authors:  Alfredomaria Lurati; Luca Bertani; Mariagrazia Marrazza; Katia Angela Re; Daniela Bompane; Magda Scarpellini
Journal:  Biologics       Date:  2012-04-11

Review 8.  The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their Products.

Authors:  Luc Van Kaer; Vrajesh V Parekh; Lan Wu
Journal:  Front Immunol       Date:  2015-05-13       Impact factor: 7.561

9.  Structural and Functional Changes of the Invariant NKT Clonal Repertoire in Early Rheumatoid Arthritis.

Authors:  Salah Mansour; Anna S Tocheva; Joseph P Sanderson; Lyndsey M Goulston; Helen Platten; Lina Serhal; Camille Parsons; Mark H Edwards; Christopher H Woelk; Paul T Elkington; Tim Elliott; Cyrus Cooper; Christopher J Edwards; Stephan D Gadola
Journal:  J Immunol       Date:  2015-11-09       Impact factor: 5.422

10.  Relationship between NK Cell Activation and Clinical Response in Rheumatoid Arthritis Treated with Rituximab.

Authors:  A Lurati; M G Marrazza; K A Re; M Scarpellini
Journal:  Int J Biomed Sci       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.